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Bloom’s syndrome (BS) is a genetic disorder associ-
ated with short stature, fertility defects, and a predispo-
sition to the development of cancer. BS cells are char-
acterized by genomic instability; in particular, a high
rate of reciprocal exchanges between sister-chromatids
and homologous chromosomes. The BS gene product,
BLM, is a helicase belonging to the highly conserved
RecQ family. BLM is known to form a complex with the
RAD51 recombinase, and to act upon DNA intermediates
that form during homologous recombination, including
D-loops and Holliday junctions. Here, we show that BLM
also makes a direct physical association with the
RAD51L3 protein (also known as RAD51D), a so-called
RAD51 paralog that shows limited sequence similarity
to RAD51 itself. This interaction is mediated through
the N-terminal domain of BLM. To analyze functional
interactions between BLM and RAD51L3, we have puri-
fied a heteromeric complex comprising RAD51L3 and a
second RAD51 paralog, XRCC2. We show that the
RAD51L3-XRCC2 complex stimulates BLM to disrupt
synthetic 4-way junctions that model the Holliday junc-
tion. We also show that a truncated form of BLM, which
retains helicase activity but is unable to bind RAD51L3,
is not stimulated by the RAD51L3-XRCC2 complex. Our
data indicate that the activity of BLM is modulated
through an interaction with the RAD51L3-XRCC2 com-
plex, and that this stimulatory effect on BLM is depend-
ent upon a direct physical association between the BLM
and RAD51L3 proteins. We propose that BLM co-oper-
ates with RAD51 paralogs during the late stages of ho-
mologous recombination processes that serve to restore
productive DNA replication at sites of damaged or
stalled replication forks.
Bloom’s syndrome (BS)1 is a rare, autosomal recessive disor-
der characterized by proportional dwarfism, immunodefi-
ciency, subfertility, and a greatly increased incidence of a wide
range of cancers (1, 2). Cell lines derived from individuals with
BS display a number of abnormalities, including poor growth
and plating, and a strikingly high level of chromosomal insta-
bility (3, 4). The characteristic feature of BS cells, which is used
in diagnosis of the disorder, is an elevated frequency of genetic
recombination events, particularly sister-chromatid exchanges
(SCEs) (5). However, this hyper-recombination is not limited to
exchanges between sister-chromatids, because interchromo-
somal homologous recombination also occurs at an elevated
rate in BS cells (1, 2)
The gene mutated in BS, which is designated BLM, is located
on chromosome 15q26.1, and encodes a protein comprising
1417 amino acids with a predicted Mr of 159,000 (6). BLM
belongs to the highly conserved RecQ family of DNA helicases
(3, 4). Because members of the RecQ family have been identi-
fied in all organisms, it seems likely that they perform an
important and conserved cellular function. There is a single
family member in bacterial and yeast species, but at least five
in human cells. Of the five human RecQ-related proteins, de-
fects in three are associated with established genetic disorders.
In addition to inactivation of BLM in BS, defects in WRN cause
Werner’s syndrome (7), and defects in RECQ4 cause Roth-
mund-Thomson syndrome (8). Like BS, both of these disorders
are associated with a high incidence of cancers, although the
primary manifestations of Werner’s syndrome and Rothmund-
Thomson syndrome are premature aging, and skin and skeletal
abnormalities, respectively. Where studied, all RecQ helicases
unwind simple, partial-duplex DNA molecules in a 3-5 direc-
tion but are notable for their atypical profile of preferred DNA
substrates (9). For example, RecQ helicases, including BLM,
are apparently unique among helicases in their ability to effi-
ciently disrupt “alternative” (non-Watson-Crick) DNA struc-
tures, including G-quadruplexes, that can form in guanine-rich
sequences such as telomeric repeat DNA (9–13). Moreover,
RecQ helicases selectively bind to at least two DNA structures
that arise during the process of homologous recombination.
BLM can disrupt synthetic oligonucleotides that mimic the
DNA displacement loop (D-loop) structure generated by DNA
strand invasion of single-stranded DNA (ssDNA) into an ho-
mologous duplex (14). BLM, WRN, and RecQ also unwind syn-
thetic 4-way junctions (X-junctions) that model the Holliday
junction recombination intermediate (9, 15, 16), and BLM and
WRN have been shown to catalyze efficient and extensive
branch migration of RecA-generated Holliday junctions (15,
17).
The process of homologous recombination in eukaryotic cells
requires several proteins, of which the central player is RAD51,
the eukaryotic ortholog of Escherichia coli RecA (18, 19).
RAD51 forms helical filaments on DNA and catalyzes DNA
strand invasion and exchange. It is assisted in these processes
by the actions of several proteins, including RAD52, RAD54,
and replication protein A. In Saccharomyces cerevisiae, a het-
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erodimer of the Rad55 and Rad57 proteins acts as a ScRad51
accessory factor, and stimulates ScRad51-mediated DNA
strand transfer activity in vitro (20, 21). Rad55 and Rad57 are
so-called Rad51 paralogs, because they show limited sequence
similarity to Rad51, but do not appear to form nucleoprotein
filaments or directly catalyze DNA strand invasion/exchange.
In human cells, there are five RAD51 paralogs, although it is
unclear whether any of these can strictly be considered as the
direct counterpart of yeast Rad55 or Rad57. The human RAD51
paralogs are termed RAD51L1 (also known as RAD51B),
RAD51L2 (RAD51C), RAD51L3 (RAD51D), XRCC2, and
XRCC3 (22–30). The RAD51L2, XRCC2, and XRCC3 proteins
are defective in hamster cell mutants (designated irs3, irs1,
and irs1SF, respectively) isolated on the basis of hypersensi-
tivity to ionizing radiation (31). These mutants also show hy-
persensitivity to a variety of other DNA damaging agents,
including DNA cross-linking chemicals, as well as extensive
genomic instability (23, 32–34). The human RAD51 paralogs
form complexes with each other, but not obviously with RAD51
itself. Various complexes have been purified, including
RAD51L2-XRCC3, RAD51L3-XRCC2, RAD51L1/L2, and a
larger complex containing RAD51L1/L2/L3-XRCC2 (35–39).
The biochemical properties of these complexes have not been
characterized in detail, and it still remains unclear why five
RAD51 paralogs exist in human cells and what their respective
functions might be. Apart from an ATPase activity that is
stimulated by DNA, little is known about the catalytic activi-
ties displayed by the human RAD51 paralogs. One possible
role, identified through an analysis of the RAD51L1/L2 com-
plex, is to assist RAD51 in the assembly of a nucleoprotein
filament on ssDNA through modulating the action of replica-
tion protein A (38). Although there is no conclusive evidence for
a direct interaction between human RAD51 and the human
RAD51 paralogs, it is clear that the action of RAD51 in vivo is
influenced by the presence of the paralogs. The most striking
manifestation of this is the failure of RAD51 to localize nor-
mally to discrete nuclear foci (thought to be sites of ongoing
DNA repair) following exposure to ionizing radiation in the
irs1, irs1SF, and irs3 cell lines discussed above (40–42).
In addition to their promotion of DNA transactions associ-
ated with homologous recombination (such as Holliday junction
branch migration), RecQ helicases interact physically with
components of the homologous recombination machinery. For
example, several RecQ helicases associate with and are stim-
ulated by replication protein A (43–45). It is not clear, however,
whether this is relevant to a role for the complex in DNA
recombination or replication. More specifically for recombina-
tion, there is a conserved interaction between RecQ helicases
and RAD51; both between the human BLM and RAD51 pro-
teins, and between the sole RecQ helicase in S. cerevisiae,
Sgs1p, and the ScRad51 protein (46). This interaction is medi-
ated by the same domain of the RecQ helicase protein (the
extreme C-terminal region in each case) (46) despite a lack of
obvious sequence similarity between the C-terminal regions of
the BLM and Sgs1 proteins.
In view of the numerous biochemical and genetic connections
between RecQ helicases and components of the homologous
recombination machinery, we have analyzed whether BLM
might interact with the human RAD51 paralogs. Here, we
show that the N-terminal domain of BLM binds to the
RAD51L3 protein. To address whether this interaction has
functional effects on the catalytic activity of BLM, we have
purified RAD51L3 in complex with its RAD51 paralog partner,
XRCC2. We show that the RAD51L3-XRCC2 heteromeric com-
plex can stimulate the ability of BLM to disrupt model Holliday
junction structures, and that this stimulatory effect requires
that BLM be capable of interacting physically with the
RAD51L3-XRCC2 complex. We present a model whereby BLM
cooperates with the homologous recombination machinery to
process DNA structures that arise at sites of blocked replica-
tion forks in human cells.
MATERIALS AND METHODS
Construction of Plasmids—The plasmids pJB1.1, pJB1.2, pJB3.1,
and pJB3.2 have been described previously (47). These plasmids, re-
spectively, contain the full-length XRCC2 open reading frame (ORF)
cloned into pGEX4T-1 and pET30a, or the full-length RAD51L3 ORF
cloned into pET30a and pGEX4T-1. pJB3.21 was generated by cloning
the full-length open reading frame for RAD51L3 into pET21a using
EcoRI and NotI sites. The 3 primer contained an in-frame stop codon.
For two-hybrid analyses, previously reported 3 constructs of the
BLM cDNA were utilized (48). These encode the C-terminal domain of
BLM from residues 966 to 1417. The RAD51L3 and XRCC2 ORFs were
cloned directionally (using 5 EcoRI and 3 NotI sites) into the pEG202
yeast two-hybrid “bait” plasmid, to generate pEG3.1 and pEG1.1, re-
spectively. The same ORFs were also cloned into the EcoRI site of the
2-hybrid “prey” plasmid, pJG45, to generate pJG3.1 and pJG1.1, re-
spectively. The oligonucleotides used in the PCR amplification of the
ORFs can be obtained upon request. All constructs were verified by
DNA sequencing.
Yeast Two-hybrid Analysis—Yeast two-hybrid screens were con-
ducted essentially as described by Wu et al. (46). Briefly, the XRCC2 or
RAD51L3 cDNAs were cloned into the plasmid pEG202 (a gift from Dr.
R. Brent) to allow expression of XRCC2 or RAD51L3 bait protein as a
fusion to LexA under control of the ADH promoter. RAD51L3 or XRCC2
were also cloned into plasmid pJG45 (a gift from Dr. R. Brent) to create
a translational fusion prey under control of the GAL1 galactose induc-
ible promoter (49). Plasmids were transformed into yeast strain EGY48,
containing the reporter plasmid pSH1834, using the lithium acetate
method, as published previously (50). Transformants were selected at
30 °C on SD-agar lacking histidine, tryptophan, and uracil.
Colonies were streaked onto YPD agar plates, which were incubated
at 30 °C overnight, before colonies were replica plated onto SD-agar
containing galactose, raffinose, and 5-bromo-4-chloro-3-indolyl--D-ga-
lactopyranoside (X-gal), but lacking histidine, tryptophan, uracil, and
leucine. Colonies were considered positive if they grew and turned blue,
after overnight incubation at 30 °C. Control proteins, including
hRAD51, LexMax, and HM12, were used as preys to assess the speci-
ficity of the interaction (51). Further two-hybrid experiments were
performed, using fragments of BLM (see Fig. 1) as either bait or prey
proteins. Quantitative -galactosidase assays on liquid cultures were
performed as described previously (47).
Preparation of Extracts from Human Cell Lines—Whole cell extracts
from human cells were prepared by washing cells in PBSA and then
boiling in SDS-PAGE protein loading buffer. Nuclear extracts were
prepared from exponentially growing HeLa S3 cells in suspension.
Approximately 2 108 cells were harvested by centrifugation, the pellet
was washed in PBSA, and the cells were lysed in 5 ml of buffer (10 mM
Tris-HCl, pH 7.5, 1.5 mM MgCl2, 10 mM NaCl, 1% (v/v) Nonidet P-40, 1
mM DTT), supplemented with protease and phosphatase inhibitors (1
mM sodium fluoride, 1 mM -glycerophosphate, 1 mM sodium orthovana-
date, 5 mM sodium pyrophosphate, 1 mM glucose 1-phosphate, 10 nM
microcystin, 0.1 mM para-nitrophenylphosphate, 1 mM phenylmethyl-
sulfonyl fluoride, and complete protease inhibitor mixture tablets
(Roche Diagnostics) according to the manufacturer’s instructions) on ice
for 45 min. Nuclei were harvested by centrifugation at 5000  g for 5
min and the remaining supernatant designated as the “cytoplasmic”
fraction. The nuclear pellet was re-suspended in 0.3 ml of TKM buffer
(50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 25 mM KCl, 1 mM DTT, supple-
mented with protease and phosphatase inhibitors as described above),
to which 0.6 ml of buffer D (80 mM Tris-HCl, pH 7.5, 2 mM EDTA, 530
mM NaCl, 1 mM DTT, supplemented with protease and phosphatase
inhibitors as above) was added, before incubation on ice for 30 min. The
nuclear extract was cleared by centrifugation at 14,000 rpm in a mi-
crocentrifuge at 4 °C, and used on the day of preparation.
Co-immunoprecipitations—All steps were performed at 4 °C unless
indicated otherwise. Nuclear and cytoplasmic extracts were made as
described above. IHIC42 (anti-RAD51L3), IHIC48 (anti-XRCC2) (47), or
appropriate preimmune sera were added to the extract at a dilution of
1:100, and the mixture was incubated on ice for 1 h. 100 l of a 50%
(w/v) slurry of protein A-Sepharose (in TKM/buffer D; ratio 1:2) was
added, and the mixture was rotated end over end for 30 min at 4 °C. The
immunoprecipitates were harvested in a microcentrifuge at 14,000 rpm
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for 5 s, and the pellet was washed with 1 ml of TKM/buffer D (ratio 1:2).
The pellet was washed a further five times in the same buffer, before
being boiled in protein loading buffer. Samples were separated by
SDS-PAGE, transferred to nitrocellulose membrane, and Western blot-
ted using conventional methods.
GST “Pull-down” Experiments—Purified RAD51L3-GST or XRCC2-
GST fusion proteins were bound to glutathione-agarose columns as
described previously (46, 47) using a typical bed volume of 0.5 ml. All
constructs for expression of GST fusion proteins have been described
previously (47, 48), except for N1-RAD51L3-GST, which was generated
using PCR to eliminate the first 120 codons of the RAD51L3 cDNA.
Briefly, purified recombinant protein or nuclear extracts were loaded
onto the column at 4 °C, and the resin was washed with 15 ml of
TKM/buffer D. The column matrix was boiled in protein sample loading
buffer and the eluted proteins were separated by SDS-PAGE before
Western blotting.
Far Western Blotting Analysis—Typically, 0.2–0.5 g of each
polypeptide was subjected to SDS-PAGE and transferred to Hybond
C-extra nitrocellulose membranes using a TE 70 semi-dry transfer unit
(Hoeffer). All subsequent steps were performed at 4 °C. Filters were
immersed twice in denaturation buffer (6 M guanidine HCl in PBSA) for
10 min, and then incubated for 6  10 min in serial dilutions (1:1) of
denaturation buffer with PBSA supplemented with 1 mM DTT. Filters
were blocked in PBSA containing 10% (w/v) powdered low fat milk,
0.1% (v/v) Tween 20 for 30 min before being incubated with purified
recombinant RAD51L3 protein (47) in PBSA supplemented with 0.25%
(w/v) milk, 0.1% (v/v) Tween 20, 1 mM DTT, and 1 mM phenylmethyl-
sulfonyl fluoride for 60 min. Filters were washed for 4  10 min in
PBSA containing 0.25% (w/v) powdered low fat milk, 0.1% (v/v) Tween
20. The second wash contained 0.00001% (v/v) glutaraldehyde. Conven-
tional Western analysis was then performed to detect the presence of
RAD51L3 using IHIC42 as the primary antibody. An otherwise identi-
cally treated negative control blot was processed, but without any
incubation with RAD51L3.
Purification of the RAD51L3-XRCC2 Complex—BL21(DE3) bacteria
were transformed simultaneously with pJB3.21 and pJB1.2, and trans-
formants were selected on LB agar containing ampicillin and kanamy-
cin. Cultures of the doubly transformed bacteria were grown in LB
medium containing ampicillin and kanamycin at 37 °C to an A600 of 0.6
before addition of isopropyl-1-thio--D-galactopyranoside to a final con-
centration of 0.4 mM. After 2 h of incubation with shaking, the culture
was cooled to 4 °C in iced water for 15 min, and the cells were harvested
by centrifugation. The cell pellet was re-suspended in 25 mM Tris-HCl,
pH 7.5, 250 mM NaCl (1 ml of buffer per 40 ml of original bacterial
culture volume), and the suspension was frozen at 80 °C. Following
thawing of the suspension, all procedures were carried out at 4 °C
unless stated otherwise. 0.2% (v/v) Triton X-100 and complete EDTA-
free protease inhibitor tablets (Roche Diagnostics) were added and the
mixture was incubated on ice for 30 min. Phenylmethylsulfonyl fluoride
was added to the final concentration of 1 mM immediately prior to lysis
by sonication (4  15 s at maximum amplitude with cooling on ice
between bursts). The lysate was cleared by centrifugation at 39,000 rpm
for 25 min (70 Ti rotor; Beckman) and ammonium sulfate was added to
a final concentration of 45% to precipitate proteins. Following incuba-
tion on ice for 30 min, precipitated proteins were harvested by centrif-
ugation, the pellet was re-suspended in 25 mM Tris-HCl, pH 7.5, 100 mM
NaCl, and the solution was dialyzed for 2 h against nickel binding
buffer (25 mM Tris-HCl, pH 7.5, 450 mM NaCl, 10 mM imidazole). The
solution was then subjected to nickel chelate chromatography using a
Poros MC20 column with a bed volume of 1.7 ml and a BioCAD work
station (Perceptive Biosytems). Prior to loading, the column was
charged with several bed volumes of 100 mM NiSO4, saturated with 5
bed volumes of 1.5 M imidazole in 25 mM Tris-HCl, pH 7.5, 450 mM
NaCl, and finally was equilibrated with 5 bed volumes of 10 mM imid-
azole in the same buffer. After loading of the protein sample, the column
was washed with 25 bed volumes of the loading buffer containing 100
mM imidazole. Elution was performed with an imidazole gradient of
100–500 mM in the same buffer, applied over 8 bed volumes. 1-ml
fractions were collected and those containing recombinant protein, as
determined by spectrophotometric monitoring (A280) and SDS-PAGE,
were dialyzed at 4 °C for 4 h against heparin binding buffer containing
25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT. The
dialyzed solution was loaded onto a heparin-agarose column (Pierce) at
4 °C, the column was washed with 10 bed volumes of loading buffer
containing 100 mM NaCl, and bound proteins were eluted in the same
buffer containing 600 mM NaCl. Fractions containing recombinant
RAD51 paralog proteins were identified by SDS-PAGE. These fractions
were dialyzed into buffer containing 25 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol. The dialyzed solution
was loaded onto a 1-ml FPLC Mono Q (Amersham Biosciences), the
column was washed with loading buffer containing 100 mM NaCl, and
bound proteins were eluted with a NaCl gradient from 100 to 600 mM.
The fractions were analyzed by SDS-PAGE, and those containing the
purified RAD51L3-XRCC2 complex were dialyzed overnight against
buffer containing the 25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM
EDTA, 1 mM DTT, 10% glycerol. Protein samples were stored in ali-
quots at 80 °C. Confirmation that the purified proteins were
RAD51L3 and XRCC2 was provided by Western blotting analyses of the
purified fractions using mouse monoclonal antibodies to the hexahisti-
dine tag (anti-polyhistidine; Sigma, H-1029) or the T7 tag (Novagen).
Further confirmation was provided by Western blotting with rabbit
polyclonal antibodies to RAD51L3 (IHIC42), and to XRCC2 (IHIC48),
which have been described previously (47). Protein concentration was
determined using a colorimetric assay (Bio-Rad protein assay), accord-
ing to the manufacturer’s instructions.
Preparation of Radiolabeled Oligonucleotides—200 ng of oligonucleo-
tide was incubated with 5–10 units of T4 polynucleotide kinase (New
England Biolabs), 25 Ci of [-32P]ATP (3000 Ci/mmol) in the manu-
facturer’s buffer, in a total volume of 10 l, for 30 min at room temper-
ature. The reaction was stopped by the addition of 50 l of STE buffer
(20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10 mM EDTA) before separation
of the oligonucleotide from the unincorporated ATP using a “Mini Quick
spin DNA column” (Roche Diagnostics) according to the manufacturer’s
instructions.
The synthetic 4-way junction (X-junction) was created by annealing
the four oligonucleotides described previously (15), and purified by
electrophoresis on a 10% non-denaturing polyacrylamide gel. The sub-
strates were stored at 20 °C until required.
ATPase Assays—ATPase activity was determined by the release of
[-32P]Pi from [-
32P]ATP. The assay mixture (20 l) contained 25 mM
Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 100 g/ml BSA, 100 mM
NaCl, 2.5 mM MgCl2 (or other divalent metal ion), 25 g/ml DNA (76 M
nucleotides), 200 M ATP, 50 nCi of [-32P]ATP (3000 Ci/mmol), and 1.0
M recombinant protein. After incubation at 37 °C for up to 2 h, the
reaction was stopped by the addition of 10 l of 0.5 M EDTA. 1 l of each
reaction was spotted onto CEL 300 PEI/UV254 (Polygram) thin layer
chromatography plates, which were rinsed in 100% methanol before
separation of [-32P]Pi from [-
32P]ATP in buffer containing 0.8 M LiCl,
0.8 M acetic acid. Plates were exposed on PhosphorImager screens
(Amersham Biosciences) and the percentage release of [-32P]Pi quan-
tified using ImageQuant software (Amersham Biosciences). Kcat calcu-
lations were carried out using the initial linear portion of plots of Pi
release versus reaction time.
DNA Binding Assays—5 end-labeled 32P single-stranded or double-
stranded oligonucleotides were prepared as described previously. Typ-
ically, 1 nmol of each oligonucleotide was incubated with protein in 25
mM Tris-HCl, pH 7.5, 0.1 mg/ml BSA, 1 mM DTT, and 1 mM EDTA with
or without 2 mM ATP and 2.5 mM MgCl2 at room temperature for 15
min. Protein-DNA complexes were separated on 5% non-denaturing
TBE polyacrylamide gels at 4 °C, dried onto 3MM (Whatman) filter
paper, and visualized by autoradiography.
DNA Helicase Assays—The synthetic 4-way junction (X-junction)
DNA was prepared as described previously (15). Reactions (20 l final
volume) were carried out in buffer containing 50 mM Tris-HCl, pH 7.5,
2 mM MgCl2, 2 mM ATP, 0.1 mM DTT, 100 g/ml BSA, and 0.5 mg/ml
yeast tRNA. BLM (concentration 0.5–1.5 nM) and RAD51L3-XRCC2
(concentration 1–50 nM) were pre-mixed on ice, before addition of the 5
32P-end-labeled X-junction substrate. Reactions were incubated at
37 °C for 20–45 min before being stopped and de-proteinized by the
addition of a one-fifth volume of stop buffer (5 is 100 mM Tris-HCl, pH
7.5, 100 mM MgCl2, 3% (v/v) SDS, and 10 mg/ml proteinase K). After a
further incubation at 37 °C for 30 min, samples were separated by
electrophoresis through 10% non-denaturing TBE polyacrylamide gels.
Gels were dried on 3MM (Whatman) filter paper before being visualized
on PhosphorImager screens. % DNA unwinding was quantified using
ImageQuant software (Amersham Biosciences).
RESULTS
RAD51L3 Interacts with the N-terminal Domain of BLM—To
analyze whether RAD51L3 and/or XRCC2 can interact with the
BLM helicase, yeast two-hybrid analyses were performed using
the system developed by Zervos et al. (51), as described previ-
ously (46). The full-length RAD51L3 and XRCC2 cDNAs were
cloned in-frame into both pEG202 and pJG45 (see “Materials
and Methods”). Various fragments of the N-terminal and C-
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terminal domains of BLM were also cloned into these vectors,
as described previously (46). Fig. 1A shows schematically the
various BLM fragments analyzed. When present in the
pEG202 bait plasmid, the N-terminal domain of BLM auto-
activated gene expression when expressed in EGY48 yeast
cells, even in the absence of a prey plasmid, and therefore this
construct was not studied further. This autoactivation probably
results from the presence of blocks of acid residues in the
N-terminal domain of BLM that can serve as transcriptional
activation domains. Hence, the N-terminal domain of BLM was
analyzed only in the prey plasmid. A positive interaction in the
yeast two-hybrid system (as indicated by the blue coloration of
yeast colonies) was found between the N-terminal domain of
BLM (BLM-N) and RAD51L3, but not between the C-terminal
domain of BLM and RAD51L3. The extent of interaction be-
tween the N-terminal domain of BLM and RAD51L3 was quan-
tified be measuring -galactosidase activity in yeast cultures. A
comparable level of -galactosidase activity was seen in yeast
containing BLM-N and RAD51L3 as was seen with the positive
control (RAD51L3 and XRCC2) (Fig. 1B). As expected from the
lack of blue coloration in yeast colonies, the quantitative assay
revealed background -galactosidase activity in cultures con-
taining BLM-C and RAD51L3, and those containing XRCC2
and either BLM-N or BLM-C (Fig. 1B). Despite the fact that no
interaction was found between XRCC2 and any of the BLM
fragments analyzed, the possibility remains that XRCC2 inter-
acts with the central helicase domain of BLM that was not
included in this study.
To determine whether BLM interacts with RAD51L3 in vivo,
immunoprecipitation experiments were performed. For this,
both nuclear and cytoplasmic fractions of HeLa cell extracts
were prepared, and immunoprecipitation of RAD51L3 (using
the IHIC42 antibody) or XRCC2 (using the IHIC48 antibody)
was carried out as described under “Materials and Methods.”
Preimmune sera were used as controls. BLM could be co-im-
munoprecipitated with both anti-RAD51L3 and anti-XRCC2
antibodies, but not with the preimmune serum controls (Fig.
1C). Moreover, this co-imunoprecipitation occurred only when
a nuclear protein extract was analyzed, consistent with the
known localization of BLM and the RAD51 paralogs to the
nucleus in human cells. Although the reciprocal immunopre-
cipitations were attempted (i.e. precipitation with anti-BLM
antibodies and Western blotting for RAD51L3 or XRCC2) in-
conclusive results were obtained, primarily because the intense
signal representing the immunoglobulin heavy chain masked
the region of the membrane where RAD51L3 and XRCC2
would be expected to be found (data not shown). As an alter-
native approach to confirming the interaction, pull-down ex-
FIG. 1. BLM interacts with RAD51L3. A, schematic representation of the fragments of the BLM protein used in yeast two-hybrid analyses.
The full-length BLM (top) comprises 1417 amino acids, including a central helicase domain (cross-hatched). Numbers refer to residue numbers in
BLM. B, yeast two-hybrid analysis of different bait proteins (expressed from pEG202) and prey proteins (expressed from pJG45). Data are the level
of -galactosidase (-gal) activity for each combination of bait and prey. XRCC2 and RAD51L3 were included as a positive control. Values represent
the mean of two independent experiments. C, co-immunoprecipitation of BLM with antibodies to RAD51L3 or XRCC2. Nuclear or cytoplasmic
extracts from HeLa cells were incubated with IHIC48 (anti-XRCC2), IHIC42 (anti-RAD51L3), or preimmune serum. Bound proteins were
precipitated with Protein A-Sepharose. Following extensive washing, precipitated proteins were separated by SDS-PAGE and transferred to
nitrocellulose. Filters were Western blotted with IHIC33 (anti-BLM). The positions of BLM and the immunoglobulin heavy chain marker of loading
(Ig) are indicated. WCL indicates a whole cell lysate that was run on the gel in parallel to denote the mobility of full-length BLM. D, pull-down of
BLM from a HeLa cell nuclear extract by a RAD51L3-GST fusion protein but not by GST alone. The position of BLM is indicated. Lanes WCL and
M represents a whole cell lysate and molecular mass standards, respectively.
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periments were performed on HeLa cell nuclear extracts using
a RAD51L3-GST fusion protein, or GST protein alone as a
control. Fig. 1D shows that the RAD51L3-GST fusion protein
readily pulled down BLM from the extract, whereas the control
GST fusion protein could not, confirming the specificity of the
interaction.
Next, we analyzed whether the interaction between RAD51L3
and BLM is a direct one, because the data presented thus far
could indicate that the interaction is mediated through an
adapter protein or DNA. For this section of the study, two ap-
proaches were undertaken. First, GST pull-down experiments
were performed using purified proteins. Fig. 2A shows that full-
length recombinant BLM could be pulled down both with
RAD51L3-GST and with a truncated RAD51L3-GST fusion pro-
tein, designated N1-RAD51L3-GST, which lacks the first 120
amino acids of RAD51L3. Consistent with the yeast two-hybrid
data presented above indicating that the RAD51L3 interaction
domain resides in the N-terminal domain of BLM, RAD51L3-
GST did not pull-down a truncated version of BLM (N-BLM)
lacking residues 1–212 of the BLM protein. Taken together, these
results indicate that RAD51L3 interacts directly with BLM and
that the first 212 amino acids of BLM are important for this
interaction. In contrast, the first 120 amino acids of RAD51L3
are apparently not required for mediating the interaction with
BLM.
In a second approach to confirming that RAD51L3 and BLM
interact directly, far Western blotting analysis was performed
(Fig. 2B). Three purified proteins, RAD51, BLM, and XRCC2,
were run on a standard SDS-polyacrylamide gel (panel a) and
then transferred to a nitrocellulose membrane. RAD51 and
XRCC2 were included to act as negative and positive controls,
respectively, for revealing any interaction between BLM and
RAD51L3. Two identical membranes were generated, one of
which, the “negative” blot (panel b), was incubated with buffer
alone. The “positive” blot (panel c) was incubated with purified
RAD51L3, as described under “Materials and Methods.” Both
membranes were then probed with IHIC42 to detect any
RAD51L3 bound to any of the three proteins present on the
membrane. A positive signal was seen at the positions where
BLM and XRCC2 were located, but no specific signal was seen
in the lane containing RAD51, or on the negative blot. It should
be noted that the XRCC2-specific signal was consistently stron-
ger than the BLM-specific signal on these blots, which may
reflect differences in the relative affinity of interaction between
each of these proteins and RAD51L3. These results confirm
that RAD51L3 interacts directly with both BLM and XRCC2,
and are consistent with previous data (39) suggesting a lack of
a direct interaction between RAD51L3 and RAD51.
Purification of a Heteromeric Complex of RAD51L3 and
XRCC2—Several previous analyses have indicated that the
successful purification of individual human RAD51 paralogs as
recombinant proteins is problematical. We have reported pre-
viously the isolation of RAD51L3 in limited quantities (47), but
our attempts to purify XRCC2 from E. coli proved unsuccessful,
because of an inability to express the protein in a soluble form
(data not shown). We reasoned that co-expression of RAD51L3
FIG. 2. BLM interacts directly with
RAD51L3. A, RAD51L3 can pull-down
purified full-length BLM but not N-
terminal truncated BLM. RAD51L3-GST
(full-length) or an N-terminal truncated
RAD51L3 (N1-RAD51L3) were bound to
glutathione-agarose beads and incubated
with BLM or N-BLM. After extensive
washing of the beads, bound proteins
were separated by SDS-PAGE and West-
ern blotted with IHIC33 anti-BLM anti-
bodies. The position of BLM is indicated
by the arrow. The positions where the
220- and 97-kDa molecular mass stand-
ards migrated is indicated in the maker
lane by black horizontal bars. B, far West-
ern blotting analysis. BLM, hRAD51, and
XRCC2 were separated by SDS-PAGE
and proteins stained with Coomassie Blue
(panel a). Two identical membranes were
prepared for Western blotting. The nega-
tive membrane (panel b) was incubated
with buffer alone, whereas the positive
membrane was incubated with purified
RAD51L3. The membranes were then
probed using IHIC42 (anti-RAD51L3).
Note the positive signals in panel c in the
positions where BLM and XRCC2 are lo-
cated, but not where hRAD51 is located.
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and its partner XRCC2 may help in the solubilization of these
proteins, and therefore would permit purification of milligram
quantities of the complex. To this end, we subcloned the
RAD51L3 and XRCC2 cDNAs into the pET21a and pET30a
expression vectors, to generate pJB3.21 and pJB1.1, respec-
tively (see “Materials and Methods”). pJB3.21 directs expres-
sion of RAD51L3 including an N-terminal T7 epitope tag,
whereas pJB1.2 directs expression of an N-terminal hexahisti-
dine-tagged XRCC2 protein. The two constructs were co-trans-
formed into E. coli BL21(DE3) cells and the proteins were
induced by treatment of the culture with isopropyl-1-thio--D-
galactopyranoside (see “Materials and Methods”). The complex
of RAD51L3-XRCC2 proteins was then purified by ammonium
sulfate precipitation, followed by chromatography on nickel
chelate resin, and heparin-Sepharose and FPLC Mono Q col-
umns. The RAD51L3 and XRCC2 protein co-purified through
all of these purification steps and the RAD51L3-XRCC2 com-
plex was judged to be greater than 95% pure following Mono Q
chromatography (Fig. 3A). Based on Coomassie Blue staining,
it would appear that the RAD51L3 and XRCC2 proteins are
present in approximately equal proportions in the purified
complex. Western blotting with anti-His tag antibodies (for
XRCC2) or anti-T7 tag antibodies (for RAD51L3) (Fig. 3B)
indicated that the two purified proteins did indeed represent
RAD51L3 and XRCC2. This was confirmed using the IHIC42
and IHIC48 antibodies specific for RAD51L3 and XRCC2, re-
spectively (47). A similar scheme for co-expression of the
RAD51L3-XRCC2 complex has been reported recently by oth-
ers (35).
Biochemical Properties of the RAD51L3-XRCC2 Com-
plex—In addition to utilizing the purified RAD51L3-XRCC2
complex for an analysis of possible interactions with BLM, we
also investigated some of the possible biochemical properties of
the complex itself. It is well established that RAD51 is a weak
ATPase. We have shown previously that RAD51L3 is also a
weak ATPase, with maximal stimulation being observed when
ssDNA is used as a co-factor (47). We found that the purified
RAD51L3-XRCC2 complex possessed an ATPase activity that
was substantially stimulated by ssDNA, but less strongly stim-
ulated by double strand DNA (Fig. 4). The ATPase activity of
the complex required Mg2 ions, although Mn2 (but not Zn2
or Co2) ions could substitute to some extent (10% of the rate
in the presence of Mg2). The optimal Mg2 ion concentration
was 1–2 mM (data not shown). The turnover number (Kcat) for
the ATPase activity of RAD51L3-XRCC2 in the presence of
ssDNA was determined to be 0.34 molecules of ATP hydro-
lyzed/min/protein monomer, marginally above that for
RAD51L3 alone (0.26) or for RAD51 protein (0.17). There was
no indication of a synergistic stimulation of ATPase activity
when RAD51 and the RAD51-XRCC2 complex were mixed in
various ratios (data not shown). In common with RAD51L3, the
RAD51L3-XRCC2 complex was shown using gel retardation
assays to bind to ssDNA, but less efficiently to double strand
DNA (data not shown). Additional biochemical analyses per-
formed on the RAD51L3-XRCC2 complex are reviewed under
“Discussion.”
The RAD51L3-XRCC2 Complex Interacts Functionally with
the BLM Helicase—Because of the connections between BLM,
the RAD51L3-XRCC2 complex, and homologous recombination
reactions, we next analyzed whether BLM might interact func-
tionally with this RAD51 paralog complex. To this end, we
studied the efficiency with which BLM can disrupt a synthetic
4-way junction (X-junction) that is a model for the Holliday
junction recombination intermediate in the presence and ab-
sence of the RAD51L3-XRCC2 complex. The data in Fig. 5, A
and B, show that the rate of BLM-mediated disruption of the
synthetic Holliday junction was increased 3-fold in reactions
containing the RAD51L3-XRCC2 complex. Incubation of the
substrate with the paralog complex alone gave no detectable
junction unwinding, indicating that the stimulation of BLM
was not because of the presence of a contaminating helicase/
branch migration protein in the paralog complex preparation.
One trivial explanation for the stimulation of BLM by
RAD51L3-XRCC2 is that the paralog complex binds to the
ssDNA-containing products of the BLM reaction, and that by
doing so relieves product inhibition of the reaction and/or pre-
vents renaturation of the substrate. This possibility can be
eliminated, however, because it is known that the E. coli single
strand-binding protein, an avid ssDNA binding factor, does not
stimulate BLM activity (44).
As discussed above, residues 1–212 of BLM appear to be vital
in mediating the interaction with RAD51L3. We have reported
previously the purification of a truncated form of BLM (termed
BLM-NC) that lacks residues 1–212, as well as the final 150
amino acids at the C-terminal end of the protein (52). The
BLM-NC protein is catalytically active, and has been shown to
unwind the same broad range of DNA substrates as reported
for the full-length BLM protein, including 3-tailed partial du-
plexes and G-quadruple DNA (52). In the current study, we
showed that the BLM-NC protein was also able to disrupt a
synthetic X-junction in a time- and concentration-dependent
FIG. 3. Co-expression and purification of a heteromeric com-
plex of RAD51L3 and XRCC2. A, the RAD51L3 and XRCC2 proteins
were co-expressed in E. coli as described under “Materials and Meth-
ods.” Protein extracts were prepared from uninduced (U) or induced (I)
bacterial cultures (left panel), and the complex was purified by nickel
chelate chromatography (Ni), heparin affinity chromatography (Hep),
and FPLC Mono Q chromatography (Q) (right panel). The positions of
the XRCC2 and RAD51L3 proteins are indicated on the right. M de-
notes molecular mass standards. B, Western blot using anti-His tag
antibodies (for XRCC2; left panel) and anti-T7 tag antibodies for
RAD51L3 (right panel) of the purified RAD51L3-XRCC2 complex.
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manner (Fig. 5, C and D, and data not shown). In contrast to
the results presented in Fig. 5A, we were unable to demon-
strate any modulation of BLM-NC-mediated X-junction un-
winding activity by the RAD51L3-XRCC2 complex. These data
indicate that the stimulation of the activity of full-length BLM
by the paralog complex requires that the BLM and RAD51L3
proteins be able to interact physically. These results also con-
firm that the observed stimulation of full-length BLM is not a
nonspecific effect either of ssDNA binding by the paralog com-
plex, or of overall protein concentration in reactions containing
the RAD51L3-XRCC2 complex. Consistent with this, we also
did not observe stimulation of BLM by the addition to unwind-
FIG. 4. The RAD51L3-XRCC2 com-
plex is a DNA-stimulated ATPase.
Time course of ATP hydrolysis catalyzed
by the RAD51L3-XRCC2 complex in the
presence or absence of ssDNA or double
strand DNA co-factor. Heat-denatured
protein was used as the negative control.
FIG. 5. The RAD51L3-XRCC2 complex stimulates BLM to disrupt a synthetic 4-way junction. A, autoradiograph of an X-junction
disruption assay. A time course of reactions containing 4 nM BLM alone or 4 nM BLM plus 20 nM RAD51L3-XRCC2 (L3/X) complex (as indicated
above the lanes). The positions of the 4-way junction substrate, the two forms of 2-way junctions products, and the fully unwound ssDNA product
are indicated diagrammatically on the right. Control lanes: Pos, Neg (both far left), and L3/X (far right) represent boiled substrate, no protein
control, and a reaction lacking BLM but containing RAD51L3-XRCC2, respectively. B, quantification of the data from panel A. C, identical 4-way
junction disruption assays to those shown in panel A, except BLM was replaced by the truncated BLM-NC protein. D, quantification of the data
from panel C.
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ing reactions of other “nonspecific” proteins, such as BSA or
GST (data not shown).
DISCUSSION
We have shown that the BS gene product, BLM, interacts
physically and directly with the RAD51L3 protein. This inter-
action is mediated by the N-terminal domain of BLM. We have
purified RAD51L3 in a complex with its RAD51 partner para-
log, XRCC2, and shown that this complex can stimulate the
ability of BLM to disrupt a synthetic Holliday junction
substrate.
We have presented several lines of independent evidence
that BLM interacts with RAD51L3. This interaction is direct,
as evidenced by the finding that the two purified proteins can
form a complex in vitro. Similarly, BLM interacts directly with
RAD51 itself (46). Although we were able to co-immunoprecipi-
tate BLM and XRCC2 from HeLa cell nuclear extracts, we
obtained no evidence for a direct interaction between these two
proteins. The most likely explanation for this co-immunopre-
cipitation is that the association is mediated by RAD51L3
serving as a protein bridge between BLM and XRCC2. Consist-
ent with this interpretation is the now established tight asso-
ciation between RAD51L3 and XRCC2, and the indication that,
although multiple combinations of human RAD51 paralog com-
plexes have been isolated, XRCC2 appears to only associate
directly with RAD51L3 (35–38, 47). The dramatic improvement
in solubility of the recombinant RAD51 paralogs when co-
expressed in E. coli (35) is strong evidence for the functional
importance of complex formation between these different para-
logs, and suggests that RAD51L3 and XRCC2 are unlikely to
exist as isolated proteins in vivo. This interpretation is consist-
ent with results from previous studies (35–38,47).
We have shown that the RAD51L3-XRCC2 complex has a
DNA-stimulated ATPase activity and binds preferentially to
ssDNA in vitro. These properties are similar to those exhibited
by the RAD51L3 subunit alone. Indeed, the kinetic parameters
for the ATPase activity of the RAD51L3-XRCC2 complex and of
RAD51L3 alone are very similar (47), indicating that XRCC2 is
unlikely to contribute a powerful ATPase function to the com-
plex. This concurs with the recent finding that cDNAs encoding
ATP binding-defective derivatives of XRCC2 are still able to
complement defects in the irs1 cell line (XRCC2 deficient),
suggesting that at least some functions of XRCC2 are inde-
pendent of any ATPase activity associated with the protein
(42). Nevertheless, it remains possible that XRCC2 modulates
the ATPase activity of RAD51L3 under certain circumstances.
Aside from ATPase and DNA binding functions, we have
been unable to identify any other biochemical or enzymatic
properties of the RAD51L3-XRCC2 complex. These data con-
trast with the recent findings of Kurumizaka et al. (35) who
demonstrated that the RAD51L3-XRCC2 complex purified
from E. coli (using a protocol similar to that described here)
could form nucleoprotein filaments and catalyze D-loop forma-
tion. Despite rigorous attempts utilizing three independently
generated preparations of the RAD51L3-XRCC2 complex (pre-
pared in two independent laboratories) we have been unable to
confirm those findings. In our study, we found no evidence that
the RAD51L3-XRCC2 complex formed nucleoprotein filaments
or could promote D-loop formation. Moreover, the complex did
not influence the ability of RAD51 to catalyze formation of
D-loops.2 At this stage, the reason(s) for the discrepancy be-
tween our results and those of Kurumizaka et al. (35) remains
unknown and will require additional investigation. It seems
highly unlikely that our preparations of the complex are simply
inactive catalytically, because we demonstrated ATPase activ-
ity, and binding to both DNA and BLM in vitro.
We have shown that the first 212 amino acids of the N-
terminal domain of BLM are necessary for mediating an inter-
action with RAD51L3, although we cannot exclude the possi-
bility that residues that lie outside of this region may also be
important for the interaction in the BLM holoenzyme. No in-
teraction with the C-terminal domain of BLM was evident. The
extreme N-terminal region of BLM also mediates an interac-
tion with topoisomerase III protein (48). It will be interesting
to assess whether there is any competitive or cooperative bind-
ing of RAD51L3 and topoisomerase III to BLM. As discussed
above, BLM also binds directly to RAD51 (46, 53) and this
interaction is mediated via the extreme C-terminal region of
BLM (possibly with an additional N-terminal binding site), a
pattern of interaction that is conserved in yeast between the
BLM homolog, Sgs1p, and the yeast Rad51 protein (46).
Whether BLM binds simultaneously to both RAD51 and
RAD51L3 will require additional studies.
Individuals with BS are characterized by an enormously
high frequency of cancers of most types (1). Although to our
knowledge there are no human genetic disorders associated
with deficiency in RAD51 paralogs, perhaps because they are
encoded by genes essential for cell viability, there are sugges-
tions that polymorphisms in RAD51 paralog genes may influ-
ence cancer risk. Of most relevance to the current study is the
recent finding that a polymorphic variant leading to an Arg-188
to His substitution in the XRCC2 protein could be a low pen-
etrance susceptibility factor for breast cancer (54).
Mutations in BLM and RAD51 paralog genes give rise to
defects in homologous recombination. However, BLM-defective
cell lines exhibit hyper-recombination (2–5), whereas the irs1,
irs1SF, and irs3 hamster cell mutants defective in RAD51
paralog function exhibit hypo-recombination and a failure to
efficiently carry out homology-directed DNA double strand
break (DSB) repair (41, 55, 56). These phenotypic differences
might seem at odds with the results represented here showing
that BLM interacts functionally with the RAD51L3-XRCC2
complex. However, we would suggest that several lines of evi-
dence indicate that this is not the case. First, mutation of
several genes in S. cerevisiae, including MRE11 and RAD50,
which are required for some aspects of homologous recombina-
tion, can confer hyper-recombination (18). Second, there is a
conserved interaction between RecQ helicases and more than
one component of the homologous recombination machinery,
most notably between BLM/Sgs1 and the RAD51 proteins in
human and yeast cells (46, 53). Indeed, genetic analyses have
shown that mutations in SGS1 and RAD51 are epistatic for
sensitivity to several DNA damaging agents and replication
inhibitors, including methylmethanesulfonate and hydroxurea
(46). This strongly suggests that Sgs1p and Rad51p operate in
the same biochemical pathway, at least for the cellular re-
sponse to these agents. Third, BLM co-localizes with RAD51 to
sites of presumed ongoing DNA repair in cells treated with
DNA damaging agents and replication inhibitors (10, 46, 53).
This co-localization occurs following treatment of human cells
with agents, such as ionizing radiation, to which BS cells are not
obviously hypersensitive. Moreover, not only is BLM recruited to
sites of DSB repair (10, 46, 53), but it is also phosphorylated by
the ATM kinase following treatment of cells with ionizing radi-
ation (57). Finally, although BS cells are not grossly defective in
the repair of DNA DSBs, it is clear that BLM is necessary for
ensuring that DSBs are repaired with high fidelity (58, 59).
Hence, multiple lines of biochemical, genetic, and cell biological
data place BLM alongside the homologous recombination
machinery in cells undergoing repair of DNA lesions.
2 J. P. Braybrooke, J.-L. Li, L. Wu, F. Caple, F. E. Benson, and I. D.
Hickson, unpublished data.
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As alluded to above, we do not consider it likely that RecQ
helicases participate in bulk DSB repair processes such as
following exposure of cells to ionizing radiation. Indeed, evi-
dence suggests that RecQ helicases act primarily during S-
phase, probably in a role connected with homologous recombi-
nation-mediated repair of damaged replication forks (60, 61).
Indeed, it would appear that a major role (and perhaps the
primary role) of the homologous recombination machinery is in
the maintenance of the structural integrity of replication forks
(62). We propose that it is during restoration of productive
DNA synthesis following replication fork demise that the BLM,
RAD51, and RAD51 paralog proteins associate functionally in
vivo. Consistent with a role in recovery from replication fork
disruption, mutants defective in RecQ helicases, RAD51, and
RAD51 paralogs are hypersensitive to killing by agents, such
as hydroxyurea, that inhibit DNA replication (46, 63–65). A
number of possible roles exist for the RecQ helicases, RAD51,
and RAD51 paralog proteins at sites of damaged or stalled
replication forks. Given the ability of the RAD51L3-XRCC2
complex to stimulate Holliday junction disruption catalyzed by
BLM, and the known function of BLM in suppressing SCEs, we
favor a model whereby the proteins act together to process
Holliday junctions at sites of stalled forks in such a way as to
minimize recombination events associated with crossing over
(as would be required to generate SCEs). In Fig. 6, two possible,
but not mutually exclusive, roles are presented. In the first,
BLM and RAD51 proteins cooperate to “re-set” a replication
fork that has regressed at the site of a blocking lesion in the
leading strand template (Fig. 6A). This regression, which is
associated with the formation of a 4-way (Holliday) junction in
the context of a so-called “chicken-foot” structure, is caused by
annealing of the two nascent DNA strands. In the absence of a
RecQ helicase, it is proposed that the regressed fork cannot be
re-set, and instead the 4-way junction must be cleaved by an
endonuclease or a “resolvase” enzyme to create a DSB at the
site of the fork. Re-establishment of a productive fork would
then require invasion of the broken end into the homologous
sequence, in a process that has the potential to create SCEs.
In a second putative role for BLM and RAD51 paralogs, the
complex acts downstream of DNA DSB formation and DNA
strand invasion to process Holliday junctions in a manner that
excludes crossing over. One possible mechanism by which this
could occur is for BLM to act in those cases where double
Holliday junctions arise as part of DNA repair processes (such
as in the canonical DSB repair model and most models for
post-replication filling of ssDNA gaps in the lagging strand). In
this model (Fig. 6B), BLM processes the double Holliday junc-
tion structure by catalyzing branch migration of the two junc-
tions toward each other. This is proposed to convert the double
Holliday junction into a so-called hemicatenane structure. Res-
olution of this structure (decatenation) would complete the
repair process without crossover of flanking DNA markers.
This latter model has the great attraction of introducing a
plausible role for the BLM-associated topoisomerase III pro-
FIG. 6. Models for the role of BLM in conjunction with the HR
machinery in “repair” of damaged replication forks. A, chicken-
foot model for the role of RecQ helicases in replication restart. A lesion
in the leading strand template (blue triangle) blocks leading strand
synthesis. However, lagging strand synthesis can continue for a short
period. The fork can then regress, allowing the nascent strands to
anneal, creating a 4-way junction (chicken-foot). The leading strand can
then be extended (dotted red line) using the longer lagging strand as a
template. The fork can be reset, by a RecQ helicase, by “reverse” branch
migration of the 4-way junction. The leading strand has now been
extended beyond the site of the lesion, and replication can recommence.
B, post-replication gap filling model. When a fork encounters a lesion in
the lagging strand template (i) a gap may be generated in the nascent
lagging strand (ii). The gap can then be filled by the HR machinery to
generate a double Holliday junction (iii). The gap is effectively sealed by
copying the intact sister-chromatid. The HR intermediate can then be
resolved by the combined action of a branch migrating enzyme (BLM?)
pushing the two junctions toward each other to generate a hemicat-
enane (iv), followed by resolution using a type I topoisomerase, such as
topoisomerase III. Note, that the structure in panel iv is presented in a
highly schematic format with strands of identical sequence being
linked, whereas it may be that the links exist between the complemen-
tary strands depending upon the degree to which strand invasion is
accompanied by intertwining of the complementary strands.
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tein, which is known to act as a ssDNA decatenase (66), as
would be required for the removal of the hemicatenane struc-
ture. Consistent with this model, recent data suggest that the
RAD51 paralogs may also act late in homologous recombina-
tion reactions, possibly at a stage during the processing of
Holliday junctions (67). Moreover, at least one RAD51 paralog,
RAD51B, appears to bind selectively to Holliday junctions com-
pared with double strand DNA or ssDNA (68). The functional
interaction of BLM and RAD51L3-XRCC2 would be consistent
with a combined role for these proteins in the branch migration
of Holliday junctions to effect their “resolution” in ways that
exclude SCE formation.
In summary, we have shown that the BLM helicase interacts
physically and functionally with the RAD51L3-XRCC2 hetero-
meric complex. This strengthens existing data linking BLM to
processes involved in the homologous recombinational repair of
DNA damages arising during S-phase. Given the key role that
BLM plays as a tumor suppressor in humans, it is important to
extend our knowledge of the key protein interactions mediated
by BLM and to delineate in greater detail the biological roles of
these multienzyme complexes.
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